Nirsevimab's RSV Protection Didn't Extend to Second Year
(MedPage Today) -- The monoclonal antibody nirsevimab (Beyfortus) consistently performed well against respiratory syncytial virus (RSV)-related hospitalization during infants' first year after receipt but without a benefit for other hospitalizations...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.